- Home
- TOMZ vs GTBP Comparison
TOMZ vs GTBP Comparison
Compare TOMZ & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOMZ | GTBP |
|---|---|---|
| Founded | 1979 | 1965 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 13.0M |
| IPO Year | 2009 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TOMZ | GTBP |
|---|---|---|
| Price | $1.57 | $9.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.9K | ★ 381.1K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,635,927.00 | N/A |
| Revenue This Year | $48.56 | N/A |
| Revenue Next Year | $121.37 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.22 |
| 52 Week High | $2.12 | $8.82 |
Technical Indicators
Market Signals| Indicator | TOMZ | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 99.19 |
| Support Level | $0.68 | $0.38 |
| Resistance Level | $1.95 | N/A |
| Average True Range (ATR) | 0.10 | 0.65 |
| MACD | -0.03 | 1.13 |
| Stochastic Oscillator | 10.00 | 97.02 |
Price Performance
Historical ComparisonAbout TOMZ TOMI Environmental Solutions Inc.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.